Reuters logo
BRIEF-Proteostasis Therapeutics files investigational NDA for PTI-808, cystic fibrosis potentiator
June 23, 2017 / 11:14 AM / 6 months ago

BRIEF-Proteostasis Therapeutics files investigational NDA for PTI-808, cystic fibrosis potentiator

June 23 (Reuters) - Proteostasis Therapeutics Inc:

* Proteostasis Therapeutics files investigational new drug application for PTI-808, cystic fibrosis potentiator

* Proteostasis Therapeutics Inc says proteostasis plans to initiate a phase 1 study of PTI-808 in healthy volunteers in July

* Proteostasis Therapeutics Inc - by end of June, co expects to report preliminary data from mad cohorts of two different CF patient populations Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below